Five to 10% of patients with cardiovascular disease have recurrent events each year. Despite evidence in support of adding warfarin to antiplatelet agents for secondary prevention among at-risk patients, the countervailing bleeding risks have limited adoption in clinical practice. Given the potentially favorable risk profile of direct oral anticoagulants compared to warfarin, these agents have […]
Category: Anticoagulation
Use of Genotype-Guided Warfarin for Anticoagulation Control in Patients Undergoing Hip or Knee Arthroplasty
Dosing of warfarin can be inconsistent for a variety of clinical reasons and may also be influenced by patient genotype. Significant interest exists in finding more effective ways to dose warfarin but previous studies of genotype dosing have shown varied results. The Genetic Informatics Trial (GIFT) of Warfarin to Prevent DVT seeks to determine whether […]
Idarucizumab for Dabigatran Reversal
The first direct oral anticoagulant (DOAC) was approved nearly a decade ago, yet there remains apprehension in transitioning to wide-spread use despite demonstrated efficacy and ease of use. One limitation is the absence of a reversal agent for patients on DOACs who develop significant bleeding or require emergent surgery. Idarucizumab is a humanized monoclonal antibody […]